Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma

Cell(2025)10.1016/j.cell.2025.06.019Source: DataRank Database

A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma is a research paper published in Cell (2025). On theSindex it has a DataRank of 0. It has been cited 30 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access30 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 11.93)OA: greenTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (44)

Derin B. Keskin ORCID,Chloe Ran Tu,Cleo Forman,Allison P. Vanasse,Haley E. Sax

Live enrichment

PubMed:40645179 PMC:PMC12351686 OpenAlex:https://openalex.org/W4412392064

NCI NIH HHS

Grant: P30 CA006516

NCI NIH HHS

Grant: R01 CA279391

NCI NIH HHS

Grant: U54 CA272688

NCI NIH HHS

Grant: U24 CA224331

NHLBI NIH HHS

Grant: R01 HL157174

NCI NIH HHS

Grant: R50 CA251956

NCI NIH HHS

Grant: U24 CA224316

NCI NIH HHS

Grant: R01 CA229261

NCI NIH HHS

Grant: R01 CA285308

NCI NIH HHS

Grant: T32 CA207021

National Institutes of Health National Cancer Institute

FWCI

11.93

Citation Percentile

1.0%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12351686/

publisherhttps://api.elsevier.com/content/article/PII:S0092867425006853?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867425006853?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cell.2025.06.019

Fields of Study

Immunotherapy and Immune ResponsesCAR-T cell therapy researchCancer Immunotherapy and Biomarkers

MeSH Terms

IpilimumabNivolumabAdjuvants, ImmunologicAntigens, NeoplasmFemaleHumansMaleMelanomaMiddle AgedReceptors, Antigen, T-CellCD8-Positive T-LymphocytesCancer Vaccines

Keywords

ImmunogenicityImmunologyBiologyT cellAdjuvantCD8Immune systemPriming (agriculture)Ex vivoT-cell receptorVaccinationIpilimumabAntigenImmunityImmunotherapyCancer researchIn vivoMutationMelanomaVaccineCancer vaccinesNeoantigenPersonalized

Sustainable Development Goals

SDG 0: Good health and well-being

A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma

FAIR Checklist

Authors (44)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)